Form 4: Casdin Partners Master Fund Executes Cross-Trade in BioLife Solutions Inc. Shares

Casdin Partners Master Fund, L.P. engaged in a cross-trade involving 150,000 shares of BioLife Solutions Inc. common stock at a price of $17.54 per share on April 30, 2024.

Summary

• On April 30, 2024, Casdin Partners Master Fund, L.P. acquired 150,000 shares of BioLife Solutions Inc. common stock through a cross-trade at $17.54 per share.
• This transaction involved a transfer of shares from a client of Casdin Capital, LLC to Casdin Partners Master Fund, L.P.
• Following the transaction, Casdin Partners Master Fund, L.P. directly owns 8,707,165 shares.
• The reporting entities include Casdin Partners Master Fund, L.P., Casdin Capital, LLC, Casdin Partners GP, LLC, and Eli Casdin, all of whom may be deemed to indirectly beneficially own the securities.
• Each reporting person disclaims beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral. It reflects a transaction but doesn't inherently indicate positive or negative sentiment towards the company's prospects.

Positives

• The acquisition of 150,000 shares by Casdin Partners Master Fund, L.P. could be interpreted as a sign of confidence in BioLife Solutions Inc.

Management Comments

• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders, providing transparency to the market.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for individuals and entities deemed insiders, such as directors, officers, and significant shareholders (10% owners), in publicly traded companies like BioLife Solutions Inc.
• These filings are comparable to those made by insiders in similar biotechnology and life sciences companies, such as Thermo Fisher Scientific or Danaher Corporation, when they engage in transactions involving their company's stock.
• The level of detail and the information disclosed in this Form 4 are consistent with industry norms and regulatory expectations for insider trading disclosures.

Related Party Transactions

• The cross-trade between a client of Casdin Capital, LLC and Casdin Partners Master Fund, L.P. could be considered a related party transaction.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding the ownership changes of a significant shareholder.

Key Dates